{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-21-003431","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.317392+00:00","generated_at":"2026-06-29T12:24:24.901190+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PharmaCyte Biotech announces Nasdaq uplisting and pricing of $15M public offering at $4.25/unit","bullets":["Common stock begins trading on Nasdaq Capital Market under PMCB on August 10, 2021.","Public offering of 3,529,412 units at $4.25 per unit (1 share + 1 warrant); gross proceeds ~$15M.","Warrants exercisable at $4.25, immediately, expire in 5 years; pre-funded warrants also offered.","H.C. Wainwright sole book-runner; underwriter granted 30-day option for up to 529,411 additional units.","Executive officers and directors subject to 90-day lock-up from prospectus supplement date."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-21-003431","json":"https://secwatch.observer/filing/0001683168-21-003431.json","markdown":"https://secwatch.observer/filing/0001683168-21-003431.md","text":"https://secwatch.observer/filing/0001683168-21-003431.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316821003431/0001683168-21-003431-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316821003431/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T12:24:24.901190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}